THE ARVs2 in the Malaysian MOH Drug

THE ARVs2 in the Malaysian MOH Drug List and their patent status are as
follows:
1. Nucleoside reverse transcriptase inhibitors (NRTI)
Stavudine (not patented)
Didanosine (patented)
Zidovudine + Lamivudine combination (patented)
2. Protease Inhibitors
Ritonavir (not patented)
Indinavir (patented)
3. Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Efavirenz (patented)
Nevirapine (not patented)
Malaysia’s practice in providing access to ARVs at that time was as follows:
1. Monotherapy was free in MOH hospitals.

Results (Indonesian) 1:

ARVs2 di daftar obat MOH Malaysia dan status paten adalah sebagaiberikut:1. nukleosida Inhibitor transkriptase (NRTI)Stavudine (tidak dipatenkan)Didanosine (dipatenkan)AZT + kombinasi Lamivudine (dipatenkan)2. protease inhibitorRitonavir (tidak dipatenkan)Indinavir (dipatenkan)3. Inhibitor transkriptase bebas-nukleosida (NNRTI)Efavirenz (dipatenkan)Nevirapine (tidak dipatenkan)Malaysia praktek dalam menyediakan akses ke ARV pada waktu itu adalah sebagai berikut:1. monoterapi adalah gratis di rumah sakit MOH.

Results (Indonesian) 2:

THE ARVs2 di Malaysia Depkes Daftar Obat dan status paten mereka adalah sebagai
berikut:
1. Nucleoside reverse transcriptase inhibitor (NRTI)
Stavudine (tidak dipatenkan)
ddI (dipatenkan)
kombinasi Lamivudine (dipatenkan) AZT +
2. Protease Inhibitor
Ritonavir (tidak dipatenkan)
Indinavir (dipatenkan)
3. Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Efavirenz (dipatenkan)
Nevirapine (tidak dipatenkan)
praktek Malaysia dalam menyediakan akses ARV pada saat itu adalah sebagai berikut:
1. Monoterapi gratis di rumah sakit Depkes.